A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.

Also called NCT01474083

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose basic science
Phase
Phase 1/2
Enrolled
  • 248 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01474083
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01474083. Randomized; quadruple masking; primary purpose basic science. Start 2011-11 (registry gives no type); primary completion 2012-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
GK1-399 (formerly TTP399)
Intervention (Drug)
GK1-399 (formerly TTP399)
Intervention (Drug)
GK1-399 (formerly TTP399)
Intervention (Drug)
Placebo
Lead sponsor
vTv Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct01474083
Content hash
6396aa6a86c293fac98d9967a19f353b12611bf72eb8ea6ea100116e7307cdf9